# To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

Study · id `cardio:ct-nct06646354` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06646354](<https://clinicaltrials.gov/study/NCT06646354>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06646354

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 125 participants.

## Technical summary

Registry record NCT06646354. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2025-05-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 125 participants (planned count; ClinicalTrials.gov record NCT06646354, source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)
- Started: 2025-04-22 (actual) (ClinicalTrials.gov record NCT06646354, source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)
- Primary completion: 2025-05-19 (actual) (ClinicalTrials.gov record NCT06646354, source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06646354, source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06646354, source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06646354-2025-05-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
- Acronym: HODO-2224
- Condition: Hypertension
- Condition: Primary Hypercholesterolaemia
- Intervention (Drug): Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
- Intervention (Drug): Candesartan/Amlodipine
- Intervention (Drug): Candesartan/Rosuvastatin/Ezetimibe
- Lead sponsor: Hyundai Pharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hyundai Pharm (`cardio:org-hyundai-pharm`)

## Provenance

Content hash: 556446c20c043b981ae893b49ce27df836104f5057b80f9711b996c883f27237
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
